Search Results

Study Suggests Severe Hemiparesis May Be a Prehospital Tool to Triage Stroke Patients for Endovascular Treatment

August 18, 2015—Rishi Gupta, MD, et al conducted a pilot study to assess diagnostic accuracy and treatment times of stroke patients and found that severe hemiparesis could be used as a prehospital tool to triage stroke severity.

Rapid Medical’s Tigertriever Introduced in United States to Treat Ischemic Stroke

May 5, 2021—Rapid Medical announced that the first patients in the United States have been treated with the company’s FDA-cleared Tigertriever revascularization device.

TIGER Trial Results Presented for Rapid Medical’s Tigertriever to Treat Stroke

March 24, 2021—Rapid Medical announced that the company’s adjustable, fully visible Tigertriever stent retriever demonstrated superiority to existing self-expanding stent retrievers in the multicenter TIGER trial, with a statistically significant 11-point improvement in the ability to restore blood flow to the brain during ischemic stroke and equivalent safety.

Vesalio’s NeVa VS Device Launched in the United States

February 23, 2023—Vesalio announced the successful initial use of its NeVa VS device in the United States for the treatment of postaneurysmal subarachnoid hemorrhage (aSAH) cerebral vasospasm.

Vesalio’s NeVa VS Stent Receives Humanitarian Device Exemption Approval to Treat Cerebral Vasospasm After aSAH

September 15, 2022—Vesalio announced FDA approval under a humanitarian device exemption for the commercialization of the NeVa VS retrievable nitinol stent.

DISTALS Trial of Rapid Medical’s Tigertriever 13 Completes Enrollment

December 9, 2025—Rapid Medical announced the completion of patient enrollment in the multicenter, randomized DISTALS trial assessing the company’s Tigertriever 13 device to treat patients with distal medium vessel occlusions (DMVO) in acute ischemic stroke.

FDA Clears Rapid Medical’s Adjustable Tigertriever for Ischemic Stroke Treatment

March 25, 2021—Rapid Medical announced FDA clearance of the company’s Tigertriever revascularization device for use in the treatment of ischemic stroke.

Rapid Medical’s Tigertriever Approved in Japan

December 13, 2023—Rapid Medical, a developer of neurovascular devices, announced that Japan’s Pharmaceuticals and Medical Devices Agency has approved the company’s Tigertriever revascularization device for mechanical thrombectomy.

Enrollment Completed Early for TIGER Study of Rapid Medical's Tigertriever Thrombectomy Device

April 7, 2020—Rapid Medical, an Israel-based developer of next-generation neurovascular interventional devices, announced that it has completed enrollment ahead of schedule in the TIGER study, which is evaluating the performance of the company's Tigertriever thrombectomy device for the acute treatment of ischemic stroke.

DISTALS Results Presented for Rapid Medical Tigertriever 13 in MVO Stroke

February 9, 2026—Rapid Medical announced late-breaking results from the DISTALS trial evaluating the company’s Tigertriever 13 device for the treatment of patients with medium vessel occlusion (MVO) ischemic stroke.

Penumbra Launches Max System Reperfusion Catheters for Treating Acute Ischemic Stroke


June 18, 2012—Penumbra, Inc. (Alameda, CA) announced the launch of its Max system of reperfusion catheters for removal of clots in patients experiencing acute ischemic stroke.  
The company stated that as an addition to its family of aspiration thrombectomy devices, the Max system neurointerventional devices allow for a fast, simplified cerebral thrombectomy procedure conducted by a single operator with over-the-wire delivery and without the need for a large proximal balloon guide.

Rapid Medical’s Tigertriever Thrombectomy Device Gains Approval in China

August 31, 2023—Rapid Medical, an Israel-based developer of neurovascular devices, announced that the company’s Tigertriever revascularization device has received approval from China’s National Medical Product Administration.

Rapid Medical’s Tigertriever 13 Receives IDE Approval for DISTALS Trial of Stroke Treatment

November 3, 2021—Rapid Medical announced FDA investigational device exemption (IDE) approval for a trial to expand interventional stroke treatment to distal regions of the brain.

Rapid Medical’s Tigertriever Evaluated in Complex Ischemic Stroke Patients with ICAD

November 16, 2023—Rapid Medical, a developer of neurovascular devices, announced new data demonstrating first-pass treatment success with the company’s Tigertriever device in complex ischemic stroke patients with underlying intracranial atherosclerotic disease (ICAD), with negligible complication rates.

SIR Announces Multisociety Guidelines for Endovascular Treatment of Stroke

January 29, 2013—The Society of Interventional Radiology (SIR) announced the publication of the first outcome-based guidelines for the interventional treatment of acute ischemic stroke.